Essential Nutrient Interactions: Does Low or Suboptimal Magnesium Status Interact with Vitamin D and/or Calcium Status?1,2

Andrea Rosanoff,3* Qi Dai,4 and Sue A Shapses5

3 Center for Magnesium Education and Research, Hauula, HI; 4 Vanderbilt Epidemiology Center, Department of Medicine, School of Medicine, Vanderbilt University, Nashville, TN; and 5 Rutgers University, New Brunswick, NJ

ABSTRACT

Although much is known about magnesium, its interactions with calcium and vitamin D are less well studied. Magnesium intake is low in populations who consume modern processed-food diets. Low magnesium intake is associated with chronic diseases of global concern [e.g., cardiovascular disease (CVD), type 2 diabetes, metabolic syndrome, and skeletal disorders], as is low vitamin D status. No simple, reliable biomarker for whole-body magnesium status is currently available, which makes clinical assessment and interpretation of human magnesium research difficult. Between 1977 and 2012, US calcium intakes increased at a rate 2–2.5 times that of magnesium intakes, resulting in a dietary calcium to magnesium intake ratio of >3.0. Calcium to magnesium ratios <1.7 and >2.8 can be detrimental, and optimal ratios may be 2.0. Background calcium to magnesium ratios can affect studies of either mineral alone. For example, US studies (background Ca:Mg >3.0) showed benefits of high dietary or supplemental magnesium for CVD, whereas similar Chinese studies (background Ca:Mg <1.7) showed increased risks of CVD. Oral vitamin D is widely recommended in US age-sex groups with low dietary magnesium. Magnesium is a cofactor for vitamin D biosynthesis, transport, and activation; and vitamin D and magnesium studies both showed associations with several of the same chronic diseases. Research on possible magnesium and vitamin D interactions in these human diseases is currently rare. Increasing calcium to magnesium intake ratios, coupled with calcium and vitamin D supplementation coincident with suboptimal magnesium intakes, may have unknown health implications. Interactions of low magnesium status with calcium and vitamin D, especially during supplementation, require further study.

Keywords: magnesium, calcium, vitamin D, calcium/magnesium ratio, nutrient interactions, essential mineral interactions

Introduction

The role of magnesium in health physiology and metabolism has been well studied; however, its interactions with calcium and vitamin D, especially when magnesium is inadequate, are less well known. This lack of data is in contrast with the extensive literature on interactions of vitamin D with calcium. This article reviews general intakes of and assessment issues for dietary magnesium and explores interactions of magnesium with the nutrients calcium and vitamin D.

Magnesium

Health effects of inadequate magnesium intake

Magnesium status is low in populations who consume modern processed-food diets that are high in refined grains, fats, and sugars (1). Low magnesium status may lead to chronic diseases (Table 1) (2–36). For example, studies have linked low magnesium status to a greater risk of metabolic syndrome (MetS)6 (24, 27–31), type 2 diabetes (T2D) (17, 37, 38), cardiovascular disease (CVD) (7, 8, 39), skeletal disorders (32, 34, 36, 40–42), chronic obstructive pulmonary disease (43–47), and possibly some cancers (48–51). Low magnesium status has also been associated with depression (52–55) and decreased cognition (56, 57). These diseases have large human and financial costs, as reported in the Global Burden of Disease Study (58). Therefore, there is a need to explore the consequences of suboptimal magnesium status in populations consuming modern processed-food diets.

1 Supported by NIH grants ROI CA149633 and U01CA182364 (to QD) and AG12161 (to SAS). This is a free access article, distributed under terms (http://www.nutrition.org/publications/guidelines-and-policies/license/) that permit unrestricted noncommercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

2 Author disclosures: A Rosanoff, Q Dai, and SA Shapses, no conflicts of interest.

*To whom correspondence should be addressed. E-mail: arosanoff@gmail.com.

6 Abbreviations used: BMD, bone mineral density; CLMD, chronic latent magnesium deficit; CVD, cardiovascular disease; IHD, ischemic heart disease; MetS, metabolic syndrome; PTH, parathyroid hormone; T2D, type 2 diabetes; TRPM7, transient receptor potential melastatin 7; VDBP, vitamin D binding protein; 1,25(OH)2D, 1,25-dihydroxyvitamin D; 25(OH)D, 25-hydroxyvitamin D.
<table>
<thead>
<tr>
<th>Authors, year (ref)</th>
<th>Study design</th>
<th>Population</th>
<th>Magnesium exposure measurement and approach</th>
<th>Outcome endpoint</th>
<th>Outcome measure</th>
</tr>
</thead>
<tbody>
<tr>
<td>Joosten et al. 2013 (2)</td>
<td>Cohort</td>
<td>Men and women free of known CVD</td>
<td>Urinary Mg as an indicator of dietary Mg uptake; lowest quintile urinary Mg (men &lt;2.93 mmol/d, women &lt;2.45 mmol/d) vs. upper 4 quintiles; plasma Mg, followed 10 y.</td>
<td>Risk of fatal and non-fatal IHD</td>
<td>Urinary Mg: lowest quintile vs. upper 4 quintiles: HR of 1.60 (95% CI: 1.28, 2.00) (Continued)</td>
</tr>
<tr>
<td>Khan et al. 2013 (3)</td>
<td>Cohort</td>
<td>Men and women from the Framingham Offspring Study free of CVD and AF</td>
<td>Serum Mg ≤0.73 mmol/L vs. serum Mg &gt;0.73 mmol/L; followed up to 20 y</td>
<td>AF incidents</td>
<td>HR of 1.52 (95% CI: 1.00, 2.31) with hypomagnesemia (serum Mg ≤0.73 mmol/L)</td>
</tr>
<tr>
<td>Misialek et al. 2013 (4)</td>
<td>Cohort</td>
<td>Men and women free of AF in the ARIC study</td>
<td>Quintiles of dietary and serum Mg (middle serum Mg quintile ≥0.80–0.83 mmol/L)</td>
<td>AF risk</td>
<td>Dietary Mg: no association observed with AF Circulating Mg: lowest serum Mg quintile compared with middle quintile (HR: 1.34; 95% CI: 1.16, 1.54); other serum Mg quintiles compared with middle quintile: no difference</td>
</tr>
<tr>
<td>Del Gobbo et al. 2012 (5)</td>
<td>Cross-sectional</td>
<td>Cree adults (&gt;18 y)</td>
<td>Hypomagnesemia (&lt;0.7 mmol/L) vs. normomagnesemia (&gt;0.7 mmol/L)</td>
<td>Prevalence of PVC</td>
<td>PVC: 50% and 20% in hypomagnemic and normomagnesemic individuals, respectively (P = 0.015)</td>
</tr>
<tr>
<td>Larsson et al. 2012 (6)</td>
<td>Meta-analysis of cohort studies</td>
<td>7 Prospective studies</td>
<td>Dose-response meta-analysis of Mg intake</td>
<td>Risk of stroke</td>
<td>Increasing dietary Mg: total risk of stroke: RR of 0.92 (95% CI: 0.88, 0.97); ischemic stroke: RR of 0.91 (95% CI: 0.87, 0.96); intracerebral hemorrhage: RR of 0.96 (95% CI: 0.84, 1.00); subarachnoid hemorrhage: RR of 1.01 (95% CI: 0.90, 1.14)</td>
</tr>
<tr>
<td>Del Gobbo et al. 2013 (7)</td>
<td>Meta-analysis of cohort studies</td>
<td>16 Studies</td>
<td>Circulating Mg: per 0.2 mmol/L dietary Mg: per 200 mg/d</td>
<td>Incidence of CVD</td>
<td>Circulating Mg: lower risk of CVD (RR: 0.70; 95% CI: 0.56, 0.88 per 0.2 mmol/L) and IHD (RR: 0.83; 95% CI: 0.75, 1.05) Dietary Mg: not significant for CVD (RR: 0.89; 95% CI: 0.75, 1.05); 22% lower risk of IHD (RR: 0.78; 95% CI: 0.67, 0.92)</td>
</tr>
</tbody>
</table>

(Continued)
<table>
<thead>
<tr>
<th>Authors, year (ref)</th>
<th>Study design</th>
<th>Population</th>
<th>Magnesium exposure measurement and approach</th>
<th>Outcome endpoint</th>
<th>Outcome measure</th>
</tr>
</thead>
<tbody>
<tr>
<td>Qu et al. 2013 (8)</td>
<td>Meta-analysis of cohort studies</td>
<td>19 Studies</td>
<td>High vs. low dietary Mg intake and serum Mg concentrations</td>
<td>Total CVD events</td>
<td>Dietary Mg: RR of 0.85 (95% CI: 0.78, 0.92) for high vs. low Mg intake; Mg intake shows significant nonlinear association with risk of CVD events. Circulating Mg: RR of 0.77 (95% CI: 0.66, 0.87) for high vs. low; only serum Mg concentrations of 0.72–0.9 mmol/L were significantly associated with total CVD event risk.</td>
</tr>
<tr>
<td>Nie et al. 2013 (9)</td>
<td>Meta-analysis of cohort studies</td>
<td>8 Studies of stroke cases</td>
<td>Dietary Mg intake; high vs. low intake plus dose-response analysis</td>
<td>Risk of stroke incidence or stroke mortality</td>
<td>Highest vs. lowest dietary Mg: risk of total stroke: RR of 0.89 (95% CI: 0.82, 0.97); risk of ischemic stroke: RR of 0.88 (95% CI: 0.80, 0.98); dose-response analysis showed a borderline inverse association between Mg intake and total stroke risk (increment of 100 mg/d), with RR of 0.98 (95% CI: 0.95, 1.0)</td>
</tr>
<tr>
<td>Alghamdi et al. 2005 (10)</td>
<td>Meta-analysis of randomized clinical trials</td>
<td>8 Trials of post–coronary artery by-pass surgery patients</td>
<td>Intravenous Mg vs. no intravenous Mg</td>
<td>Incidence of postoperative AF</td>
<td>With intravenous Mg: RR of 0.64 (95% CI: 0.47, 0.97)</td>
</tr>
<tr>
<td>Shiga et al. 2004 (11)</td>
<td>Meta-analysis of randomized clinical trials</td>
<td>17 Trials in post–cardiac surgery patients</td>
<td>Mg supplementation vs. no supplementation</td>
<td>Incidence of arrhythmias</td>
<td>With Mg supplementation: RR of 0.77 (95% CI: 0.63, 0.93) for supraventricular arrhythmias; RR of 0.52 (95% CI: 0.31, 0.87) for ventricular arrhythmias; no effect on incidence of perioperative myocardial infarction or mortality</td>
</tr>
<tr>
<td>CVD mortality</td>
<td>Cohort</td>
<td>Subjects not receiving Mg supplementation</td>
<td>Serum Mg ≤0.73 mmol/L vs. &gt;0.73 mmol/L, follow-up 10.1 y</td>
<td>CVD mortality</td>
<td>Serum Mg ≤0.73 mmol/L: 3.44 deaths/1000 person-years; serum Mg &gt;0.73 mmol/L: 1.53 deaths/1000 person-years</td>
</tr>
</tbody>
</table>

(Continued)
### TABLE 1 (Continued)

<table>
<thead>
<tr>
<th>Authors, year (ref)</th>
<th>Study design</th>
<th>Population</th>
<th>Magnesium exposure measurement and approach</th>
<th>Outcome endpoint</th>
<th>Outcome measure</th>
</tr>
</thead>
<tbody>
<tr>
<td>Chiuve et al. 2013 (13)</td>
<td>Cohort</td>
<td>Women free of disease</td>
<td>Dietary and plasma Mg quintiles</td>
<td>Risk of fatal IHD</td>
<td>Dietary Mg: comparing high with low quintiles: RR of 0.61 (95% CI: 0.45, 0.84) Circulating Mg: plasma Mg concentrations &gt;20 mg/dL were associated with lower risk but not significant (RR: 0.67, 95% CI: 0.44, 1.04)</td>
</tr>
<tr>
<td>Del Gobbo et al. 2013 (7)</td>
<td>Meta-analysis of cohort studies</td>
<td>16 Studies</td>
<td>Circulating Mg per 0.2 mmol/L; dietary Mg per 200 mg/d</td>
<td>Fatal IHD</td>
<td>Dietary Mg: nonlinear association ($P &lt; 0.001$) with inverse association at intakes &gt;250 mg/d; RR of 0.73 (95% CI: 0.62, 0.86 for &gt;250 mg/d vs. &lt;250 mg/d) Circulating Mg: RR of 0.61 (95% CI: 0.37, 1.00)</td>
</tr>
<tr>
<td>Joosten et al. 2013 (2)</td>
<td>Cohort</td>
<td>Men and women free of known CVD</td>
<td>Urinary excretion as an indication of intestinal Mg absorption, and plasma Mg followed 10 y</td>
<td>IHD mortality</td>
<td>Urinary Mg: lowest quintile compared with upper 4 quintiles: 1.70 (95% CI: 1.10, 2.61) Circulating Mg: no association with fatal IHD</td>
</tr>
<tr>
<td>All-cause mortality</td>
<td>Cohort</td>
<td>Subjects not receiving Mg Supplementation</td>
<td>Serum Mg ≤0.73 mmol/L vs. &gt;0.73 mmol/L; follow-up 10.1 y</td>
<td>All-cause mortality</td>
<td>Serum Mg ≤0.73 mmol/L: 10.95 deaths/1000 person-years; serum Mg &gt;0.73 mmol/L: 1.45 deaths/1000 person-years</td>
</tr>
<tr>
<td>Booth et al. 2003 (14)</td>
<td>Cohort</td>
<td>Patients undergoing 20% CABG surgery</td>
<td>Low Mg defined as serum Mg &lt;1.8 mmol/L at any point within 8 d after surgery</td>
<td>Death at 1 y after surgery</td>
<td>HR of 2.0 (95% CI: 1.19, 3.37) if defined low serum Mg occurred</td>
</tr>
<tr>
<td>Ishimura et al. 2007 (15)</td>
<td>Cohort</td>
<td>Patients receiving maintenance hemodialysis</td>
<td>Baseline serum (baseline Mg ≤1.14 mmol/L vs. Mg &gt;1.14 mmol/L) followed for 51 mo</td>
<td>All-cause mortality</td>
<td>Low circulating Mg: HR of 0.485 (95% CI: 0.241, 0.975), evidence of a “J curve”</td>
</tr>
<tr>
<td>Singhi et al. 2003 (16)</td>
<td>Cohort</td>
<td>Children in a PICU (6 mo–12 y)</td>
<td>Hypomagnesemic vs. normomagnesemic</td>
<td>Percentage of mortality</td>
<td>Hypomagnesemic: 30%; normomagnesemic: 3.3%</td>
</tr>
<tr>
<td>T2D</td>
<td>Cohort</td>
<td>Men and women</td>
<td>Mg intake</td>
<td>Risk of T2D</td>
<td>Inverse risk of T2D with Mg intake: RR of 0.78 (95% CI: 0.73, 0.84)</td>
</tr>
<tr>
<td>Dong et al. 2011 (17)</td>
<td>Meta-analysis of 13 cohort studies</td>
<td>Men and women</td>
<td>Mg intake</td>
<td>Risk of T2D</td>
<td>Overall RR of 0.85 (95% CI: 0.79, 0.92) for 100 mg/d increase in dietary Mg</td>
</tr>
<tr>
<td>Larsson and Wolk, 2007 (18)</td>
<td>Meta-analysis of 7 cohort studies</td>
<td>Men and women</td>
<td>Mg intake, food and supplements</td>
<td>Relative risk of T2D</td>
<td></td>
</tr>
</tbody>
</table>

(Continued)
TABLE 1 (Continued)

<table>
<thead>
<tr>
<th>Authors, year (ref)</th>
<th>Study design</th>
<th>Population</th>
<th>Magnesium exposure measurement and approach</th>
<th>Outcome endpoint</th>
<th>Outcome measure</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sales et al. 2011 (19)</td>
<td>Cross-sectional</td>
<td>T2D patients</td>
<td>Measured Mg intake plus urinary, plasma, and RBC Mg</td>
<td>Fasting glucose, 2-h postprandial glucose, and HbA1c</td>
<td>In T2D patients, 77% had Mg status measure below cut-off; all mean Mg measures were low: dietary Mg (228 ± 43 mg Mg/d), urinary Mg (2.8 ± 1.51 mmol/d), plasma Mg (0.71 ± 0.08 mmol/L), and RBC Mg (1.92 ± 0.23 mmol/L); poor blood glucose control: fasting glucose (8.1 ± 3.7 mmol/L), 2-h postprandial glucose (11.1 ± 5.1 mmol/L), HbA1c (11.4% ± 3.0%)</td>
</tr>
<tr>
<td>Agrawal et al. 2011 (20)</td>
<td>Cross-sectional</td>
<td>60 Healthy controls; study groups: 30 individuals with diabetes with no complications; 60 with diabetes plus macrovascular complications</td>
<td>Serum Mg</td>
<td>Fasting glucose, HbA1c, and serum Mg</td>
<td>Fasting glucose and HbA1c was higher in study groups vs. healthy controls; circulating Mg: low serum Mg concentrations in study groups with diabetes compared with the healthy control group (P &lt; 0.05); study groups with macrovascular complications showed significant correlation between serum Mg and fasting glucose and HbA1c (11.4% ± 3.0%)</td>
</tr>
<tr>
<td>Sharma et al. 2007 (21)</td>
<td>Cross-sectional</td>
<td>50 Participants with diabetes (types 1 and 2) vs. 40 healthy controls</td>
<td>Serum Mg</td>
<td>Participants with diabetes vs. healthy controls</td>
<td>Serum Mg lower in diabetics than in healthy individuals (P &lt; 0.005); lower in participants with diabetes with complications than in those without complications (P &lt; 0.001); duration of diabetes inversely related to serum Mg</td>
</tr>
<tr>
<td>Chambers et al. 2006 (22)</td>
<td>Cross-sectional</td>
<td>African-American and Hispanic adults (US), aged 53 ± 16 y</td>
<td>Serum Mg</td>
<td>Participants with diabetes vs. normal fasting glucose</td>
<td>Serum Mg of 0.80 ± 0.07 mmol/L in participants with diabetes and 0.84 ± 0.07 mmol/L in those with normal fasting glucose (P &lt; 0.001)</td>
</tr>
</tbody>
</table>

(Continued)
<table>
<thead>
<tr>
<th>Authors, year (ref)</th>
<th>Study design</th>
<th>Population</th>
<th>Magnesium exposure measurement and approach</th>
<th>Outcome endpoint</th>
<th>Outcome measure</th>
</tr>
</thead>
<tbody>
<tr>
<td>Saggese et al. 1991 (23)</td>
<td>RCT</td>
<td>Children with diabetes (9.4 ± 2.5 y), with age- and sex-matched controls</td>
<td>Oral Mg therapy 6 mg·kg⁻¹·d⁻¹ for 60 d</td>
<td>Serum Mg, total and ionized serum Ca, intact PTH, calcitriol, osteocalcin</td>
<td>Circulating Mg: serum Mg lower in children with diabetes than controls at baseline; with supplementation, serum Mg significantly increased, reaching levels of age- and sex-matched control values</td>
</tr>
<tr>
<td>Solati et al. 2014 (24)</td>
<td>RCT</td>
<td>Patients with T2D</td>
<td>Oral Mg 300 mg/d for 3 mo</td>
<td>Fasting blood and 2-h postprandial glucose vs. control</td>
<td>Oral Mg lowered fasting blood glucose (P &lt; 0.0001) and 2-h postprandial glucose (P &lt; 0.01)</td>
</tr>
<tr>
<td>Song et al. 2006 (25)</td>
<td>Meta-analysis of 9 randomized clinical trials</td>
<td>Patients with T2D</td>
<td>Oral Mg median dose = 360 mg/d</td>
<td>Fasting glucose in treatment vs. control groups</td>
<td>Oral Mg compared with placebo lowered fasting glucose (−0.56 mmol; 95% CI: −1.10, −0.01) but not HbA1c (−0.31%; 95% CI: −0.81, 0.19)</td>
</tr>
<tr>
<td>Yang et al. 1999 (26)</td>
<td>Case-control</td>
<td>Death from diabetes vs. other causes in Taiwan</td>
<td>Drinking water Mg concentrations</td>
<td>Deaths from diabetes and Mg concentration in drinking water</td>
<td>Protective effect of Mg intake from drinking water</td>
</tr>
<tr>
<td>MetS</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>He et al. 2006 (27)</td>
<td>Cohort</td>
<td>Healthy Americans aged 18–30 y, followed 15 y</td>
<td>Dietary Mg intake quartiles, highest vs. lowest</td>
<td>Development of MetS</td>
<td>Dietary Mg, high vs. low quartile: HR of 0.69 (95% CI: 0.52, 0.91)</td>
</tr>
<tr>
<td>Huang et al. 2012 (28)</td>
<td>Cross-sectional</td>
<td>Elderly patients with T2D; some with depression</td>
<td>Mg intake quartiles</td>
<td>Depression and variables of MetS</td>
<td>MetS and depression both associated with lower Mg intake (P &lt; 0.05); positive association between Mg intake and HDL cholesterol (P &lt; 0.005); inverse association between Mg intake and TGs, waist circumference, % body fat, and BMI (P &lt; 0.005); 88.6% had Mg intakes &lt;DRI; 37% had hypomagnesemia</td>
</tr>
<tr>
<td>Guerrero-Romero and Rodríguez-Moran, 2002 (29)</td>
<td>Cross-sectional</td>
<td>192 Individuals with MetS and 384 age- and sex-matched healthy controls</td>
<td>Compared serum Mg of MetS subjects vs. healthy controls</td>
<td>Risk of MetS with low serum Mg</td>
<td>Low serum Mg increased risk of MetS (OR: 6.8; 95% CI: 4.2, 10.9); low serum Mg found in 65.6% of patients with MetS and in 4.8% in healthy controls (P &lt; 0.00001)</td>
</tr>
</tbody>
</table>

(Continued)
TABLE 1 (Continued)

<table>
<thead>
<tr>
<th>Authors, year (ref)</th>
<th>Study design</th>
<th>Population</th>
<th>Magnesium exposure measurement and approach</th>
<th>Outcome endpoint</th>
<th>Outcome measure</th>
</tr>
</thead>
<tbody>
<tr>
<td>Solati et al. 2014 (24)</td>
<td>RCT</td>
<td>T2D patients</td>
<td>300 mg Mg/d or placebo for 3 mo</td>
<td>Variables of MetS</td>
<td>Oral Mg improved lipid profile, blood pressure, and hepatic enzymes in addition to significantly lowering fasting ($P &lt; 0.001$) and postprandial ($P &lt; 0.01$) glucose</td>
</tr>
<tr>
<td>Rodríguez-Moran et al. 2014 (30)</td>
<td>RCT</td>
<td>Metabolically obese normal-weight people with hypomagnesemia</td>
<td>382 mg Mg/d vs. placebo for 4 mo</td>
<td>Change in HOMA-IR index, fasting glucose and TG concentrations, BP</td>
<td>Oral Mg improved all MetS variables: HOMA-IR: $-46.5%$ for Mg vs. $-5.4%$ for placebo ($P &lt; 0.001$); fasting glucose: $-12.3%$ for Mg vs. $-1.8%$ for placebo ($P &lt; 0.05$); TGs: $-4.7%$ for Mg vs. $-10.1%$ for placebo ($P &lt; 0.0001$); SBP: $-2.1%$ for Mg vs. $3.9%$ for Pl ($P &lt; 0.05$). +3.9% for placebo ($P &lt; 0.05$); DBP: $-3.8%$ for Mg vs. +7.5% for placebo ($P &lt; 0.05$)</td>
</tr>
<tr>
<td>Dibaba et al. 2014 (31)</td>
<td>Meta-analysis</td>
<td>6 Cross-sectional studies</td>
<td>Compared lowest with highest dietary Mg intake groups</td>
<td>Risk of MetS</td>
<td>Lower Mg intakes had risk of MetS: OR of 0.69 (95% CI: 0.59, 0.81)</td>
</tr>
<tr>
<td>Tucker et al. 1999 (32)</td>
<td>Cohort</td>
<td>Elderly subjects, Framingham Heart Study</td>
<td>Dietary Mg intakes including supplements</td>
<td>4-y Change in BMD (3 hip sites, 1 forearm site)</td>
<td>Mg intake was associated with less BMD decline at 2 hip sites; greater BMD at 1 hip site for both men and women; greater BMD in forearm for men</td>
</tr>
<tr>
<td>Orchard et al. 2014 (33)</td>
<td>Cohort</td>
<td>Postmenopausal women (Women’s Health Initiative Observational Study)</td>
<td>High vs. low total dietary Mg intake quintile (quintile 5 $&gt;422.5$ mg/d vs. quintile 1 $&lt;206.5$ mg/d)</td>
<td>Hip fractures and whole-body BMD</td>
<td>High vs. low-Mg group: hip BMD: 3% higher in high- vs. low-Mg group ($P &lt; 0.001$); whole-body BMD: 2% higher ($P &lt; 0.001$); incidence and RR of hip fractures: no change across dietary Mg quintiles; risk of lower arm or wrist fractures increased at quintiles 4 (HR: 1.15; 95% CI: 1.01, 1.32) and 5 (HR: 1.23; 95% CI: 1.07, 1.42); women in the higher quintiles more physically active, at increased risk of falls</td>
</tr>
</tbody>
</table>

Skeletal disorders

(Continued)
In a 2011–2012 USDA survey of the latest data available for US dietary intake amounts, mean magnesium intakes for adults were below the RDA (Figure 1) (59, 60). Mean magnesium intakes from food for US adults were comparable to Estimated Average Requirement levels for all adult groups, which is consistent with 50% of the population not achieving adequate dietary magnesium intakes. In specific populations of the 2005–2006 NHANES, the magnesium intake was below the Estimated Average Requirement in diets of 48% of North Americans, 89% of teenaged girls, 55–58% of persons aged 51–70 y, and 70–80% of individuals aged ≥71 y (61, 62).

As a group, adults who use magnesium-containing dietary supplements show a mean magnesium intake above RDA levels (Figure 1); however, their calcium to magnesium dietary intake ratio is also higher, and it is substantially higher in female supplement users in particular (59, 63–70) (Figure 2). Dietary intake of magnesium has been low for several decades in the United States (72). In the 1977 USDA nutrient intake survey, the mean magnesium intake from food was 309 mg/d for men (63). In the 2011–2012 NHANES, the mean magnesium intake had increased by 15.5% ($r = 0.78$, $P = 0.013$) to 357 mg/d for men (59), which was still below the RDA of 420 mg/d. In the same 2 surveys, the mean magnesium intake from foods increased from 216 mg/d in 1977 (64) to 271 mg/d in 2011–2012 for women (59), which was an increase of 25% ($r = 0.93$, $P < 0.001$) but was still below the RDA of 320 mg/d. These increases in magnesium intake over the past 33 y were somewhat

### TABLE 1 (Continued)

<table>
<thead>
<tr>
<th>Authors, year (ref)</th>
<th>Study design</th>
<th>Population</th>
<th>Magnesium exposure measurement and approach</th>
<th>Outcome endpoint</th>
<th>Outcome measure</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ryder et al. 2005 (34)</td>
<td>Cross-sectional</td>
<td>White and black older men and women aged 70–79 y</td>
<td>Dietary Mg quintiles</td>
<td>BMD</td>
<td>BMD in white women: 0.04 g/cm² higher in high ($P = 0.05$) vs. low quintile of dietary Mg; in white men: 0.02 g/cm² ($P = 0.005$); higher whole-body BMD associated with Mg intake for white men ($P &lt; 0.05$) and white women ($P &lt; 0.005$) but no such association in black men and women</td>
</tr>
<tr>
<td>New et al. 2000 (35)</td>
<td>Cross-sectional</td>
<td>62 Healthy women aged 45–55 y</td>
<td>Mg intake from FFQ</td>
<td>Total bone mass</td>
<td>Dietary Mg intake associated with higher total bone mass: significant Pearson correlation ($P &lt; 0.05$ to $P &lt; 0.005$)</td>
</tr>
<tr>
<td>Stendig-Lindberg et al. 1993 (36)</td>
<td>Clinical study</td>
<td>54 Postmenopausal women with osteoporosis</td>
<td>31 Received oral Mg therapy for 2 y; 23 without treatment served as controls</td>
<td>Mean bone density</td>
<td>71% of Mg group responded by a 1%–8% increase in bone density, with increases at both 1 and 2 y; mean bone density of all Mg therapy patients increased after 1 y ($P &lt; 0.02$) and remained unchanged at 2 y ($P &lt; 0.05$), whereas mean bone density decreased in untreated controls ($P &lt; 0.001$)</td>
</tr>
</tbody>
</table>

1 AF, atrial fibrillation; ARIC, Atherosclerosis Risk in Communities; BMD, bone mineral density; BP, blood pressure; CABG, coronary artery by-pass grafting; ISD, ischemic heart disease; CVD, cardiovascular disease; DBP, diastolic blood pressure; HbA1c, glycated hemoglobin; IHD, ischemic heart disease; MetS, metabolic syndrome; PICU, pediatric intensive care unit; PTH, parathyroid hormone; PVC, premature ventricular complex; RCT, randomized controlled trial; ref, reference; SBP, systolic blood pressure; T2D, type 2 diabetes.
higher but comparable to the increases in food energy between these 2 surveys (i.e., kilocalorie increases of 6% and 17% for men and women, respectively).

**Magnesium physiology**

In human adults, whole-body magnesium content is ≈24 g (1 mol). Approximately half of this magnesium is present in bone and the other half is found in soft tissue, with <1% present in blood. Serum magnesium represents ≈0.3% of whole-body magnesium (73). Although the measurement of serum magnesium is useful in medical diagnoses of clinically severe magnesium deficiency (74), it may not reliably represent whole-body magnesium status. The healthy human body tightly regulates blood magnesium concentrations, maintaining a “normal” range even in times of low dietary magnesium intakes and/or excessive magnesium excretion. Both bone and soft tissue intracellular magnesium concentrations may be depleted (or depleting) while serum/plasma magnesium concentrations remain in the “healthy” range (75). Pig studies in the 1970s (76) showed that magnesium-deficient pigs had reduced intracellular magnesium from soft tissues and erythrocytes as well as reduced bone magnesium content, although serum magnesium remained at the normal concentration. This magnesium physiology appears to be similar in humans (75). Thus, in populations who have chronically low dietary magnesium intakes and high dietary calcium to magnesium ratios, such as in the United States (discussed later in this review), people who are nonsymptomatic with normal serum magnesium concentrations may have dangerously low tissue magnesium concentrations and decreasing bone magnesium content. This condition has been termed “chronic latent magnesium deficit” (CLMD) (75) and is further considered later in this review.

**Magnesium status assessment**

There is currently no simple, reliable biomarker for whole-body magnesium status, and the challenges of assessing magnesium status can impede the interpretation of human magnesium research. The currently available forms of assessment are described below.

**Magnesium load retention test as a biomarker.** The magnesium retention test is cumbersome but is considered the most reliable research indicator of whole-body magnesium status. In this test, an intramuscular or intravenous infusion of magnesium (the magnesium “load”) is given to a subject, followed by urine collection for $24$ h. The percentage of the magnesium load excreted in the urine is measured, and the percentage of the magnesium load retained by the body during the length of the urine collection is calculated. Subjects who are magnesium replete are expected to retain small percentages of the magnesium load, whereas subjects with magnesium deficits are expected to show larger retention percentages. Researchers use different retention percentages to define “magnesium deficit” with these load

**FIGURE 1** Mean magnesium intakes for US women (A) and men (B) from food alone (all adults) and from food plus supplements (supplement users only). Data are from the 2011–2012 NHANES (59) and DRIs (60). In US adults, 23% of women and 22% of men use dietary supplements that contain magnesium (59). EAR, Estimated Average Requirement.

**FIGURE 2** Increasing calcium to magnesium ratios in US women (A) and men (B) from food alone (all adults) and from food plus supplements (supplement users only). Data are from the USDA Agricultural Research Service Food Surveys for 1977 and 1985 (63, 64), 1994–1995 (65), and 2001–2012 (59, 66–70). In US adults, 23% of women and 22% of men use dietary supplements that contain magnesium (59). A calcium to magnesium ratio >2.8 interacts with a functional polymorphism in colorectal neoplasia risk (71).
TABLE 2  Varying cutoffs used in magnesium status studies to define hypomagnesemia and magnesium deficit by percentage of magnesium load retention

<table>
<thead>
<tr>
<th>Authors, year (ref)</th>
<th>Study size and location</th>
<th>Definition of hypomagnesemia by serum magnesium cutoff, mmol/L</th>
<th>Definition of magnesium deficit by magnesium load test (% retention of load)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Arnold et al. 1995 (77)</td>
<td>n = 16; ICU in Wales</td>
<td>&lt;0.6 (reference range: 0.6–1.2)</td>
<td>Retained &gt;30% magnesium load</td>
</tr>
<tr>
<td>Saur et al. 1996 (78)</td>
<td>n = 20; ICU in Germany</td>
<td>&lt;0.8 (reference range: 0.8–1.0)</td>
<td>Moderate magnesium deficit: retained &gt;20–50% magnesium load; considerable magnesium deficit: retained &gt;50% magnesium load</td>
</tr>
<tr>
<td>Hébert et al. 1997 (79)</td>
<td>n = 44 renal-sufficient patients; ICU in Ottawa, Canada</td>
<td>&lt;0.7 (reference range: 0.7–0.91)</td>
<td>Retained &gt;30% magnesium load</td>
</tr>
<tr>
<td>Ryzen et al. 1985 (80)</td>
<td>n = 94 in large county medical center ICU, Los Angeles, California</td>
<td>&lt;0.74 (reference range: 0.74–0.91)</td>
<td>&gt;40% Retention in 8 h; &gt;15% retention in 24 h; hypomagnesemic patients had 78% retention</td>
</tr>
<tr>
<td>Danielson et al. 1979 (81)</td>
<td>n = 106 apparently healthy subjects, aged 15–80 y; Sweden</td>
<td>Women: 0.82 ± 0.06 (n = 47); men: 0.83 ± 0.05 (n = 59); total range: 0.66–0.96</td>
<td>Women: 23% ± 11% retention (n = 12); men: 18% ± 11% retention (n = 22); total range: 0–38%</td>
</tr>
</tbody>
</table>

1 Magnesium load equals intramuscular or intravenous infusion of magnesium followed by urine collection for ≥24 h when the percentage of magnesium load excreted in urine is calculated. Magnesium-depleted subjects are expected to retain a larger percentage of the load than magnesium-replete subjects. ICU, intensive care unit; ref, reference.

2 Values for Danielson et al. (81) are presented as serum magnesium means and ranges and magnesium retention means and ranges by magnesium load test.

tests (77–81) (Table 2). In addition to its poorly defined cutoffs and its cumbersome nature, the magnesium load retention test cannot be used in patients with chronic kidney disease or in individuals with critical illnesses (82).

**Serum magnesium and CLMD.** The largest data source for serum magnesium reference ranges is derived from a 1971–1974 US study in 15,820 presumably healthy individuals aged 1–74 y (83), a population who may not have been fully magnesium replete (75). Serum magnesium clinical reference ranges in the United States are not evidence based and may include a subpopulation of unknown size with CLMD. The lower serum magnesium range for healthy individuals has been questioned because some studies suggested that the currently accepted lower range correlates with negative health outcomes. The criterion for low “normal” serum magnesium as a definition for hypomagnesemia varies widely in studies (Table 2) as well as among clinical laboratories, ranging from as low as 0.6 mmol/L to as high as 0.75 mmol/L (83–85, FH Nielsen, unpublished data, 2015) (Table 3). Increasing the low-normal boundary of serum magnesium to a range of 0.80–0.85 mmol/L to better accommodate the CLMD subpopulation has been suggested (75, 84, 86).

**Magnesium load retention vs. serum magnesium as a biomarker.** Data from a small (n = 16) study in Wales reported both individual serum magnesium and magnesium load retention test results for hospitalized patients (77). The study showed that differentiation between depletion and nondepletion (via the magnesium load retention test) was meaningful only when a serum magnesium value of ≥0.85 mmol/L was used as the cutoff to define hypomagnesemia (77). Serum magnesium may not be a reliable marker

TABLE 3  Healthy and unhealthy serum magnesium and vitamin D concentrations in commonly used units

<table>
<thead>
<tr>
<th>Serum magnesium</th>
<th>Serum vitamin D</th>
</tr>
</thead>
<tbody>
<tr>
<td>mmol/L</td>
<td>mg/dL</td>
</tr>
<tr>
<td>1974 NHANES</td>
<td>0.75–0.96</td>
</tr>
<tr>
<td>High normal</td>
<td>0.91–1.2</td>
</tr>
<tr>
<td>Recommended sufficient</td>
<td>&gt;0.80–0.85</td>
</tr>
<tr>
<td>Low normal</td>
<td>0.60</td>
</tr>
<tr>
<td>Low normal</td>
<td>0.70</td>
</tr>
<tr>
<td>Low normal</td>
<td>0.75</td>
</tr>
<tr>
<td>Adverse</td>
<td>&gt;150</td>
</tr>
<tr>
<td>High</td>
<td>&gt;125</td>
</tr>
<tr>
<td>Sufficient</td>
<td>50–125</td>
</tr>
<tr>
<td>Inadequate</td>
<td>30–50</td>
</tr>
<tr>
<td>Deficient</td>
<td>&lt;30</td>
</tr>
</tbody>
</table>

1 Data are from DIs for calcium and vitamin D (85).
2 Vitamin D conversion factor: multiply µg/L by 2.5 to convert to nmol/L.
4 Healthy serum magnesium reference ranges vary slightly among clinical laboratories and research studies.
5 Proposed cutoff range for a more evidence-based definition of hypomagnesemia (84, FH Nielsen, unpublished data, 2015).
of magnesium status in clinical settings or research studies partly because the accepted “normal range” in North America is not evidence based. For example, individuals in the serum magnesium range from 0.6 or 0.7 up to 0.84 mmol/L are labeled “normomagnesemic” and are thus assumed to be non–magnesium depleted when, in fact, a large portion of these persons might more accurately be designated as magnesium depleted. Well-designed studies comparing results of individual magnesium load retention tests with serum magnesium concentrations are needed to fully explore whether increasing the lower cutoff is warranted.

Value of serum magnesium as a biomarker. Additional research is needed on the proper use of serum magnesium as a biomarker of magnesium status and the possible impact of CLMD. Studies are needed to address whether there are physiologic changes to bone or soft tissue that are associated with low magnesium intakes but normal serum magnesium concentrations. In addition, proton pump inhibitors are widely prescribed and these medications significantly increase the risk of hypomagnesemia in the general population (87). Recent analysis of human magnesium balance studies suggests that serum magnesium may represent long-term, severely magnesium-deficient status, because it does not respond as rapidly or as flexibly to magnesium intake as does urinary magnesium (FH Nielsen, unpublished data, 2015). At this time, serum magnesium values can be considered a useful, but not an absolutely reliable, indicator of whole-body magnesium status when interpreting human magnesium research.

Urinary magnesium. Urinary magnesium increases with high magnesium diets and/or oral magnesium supplementation and remains low during times of low magnesium intake (88, 89). A study by Joosten et al. showed that urinary magnesium excretion is an indicator of intestinal magnesium absorption and is thus a potential marker of CVD risk (90) that is perhaps more reliable than serum magnesium (2, 89).

Calcium Magnesium interactions with calcium

In humans, it has long been known that hypomagnesemia often presents with hypocalcemia (91) and that calcium intake affects magnesium retention and vice versa (see below). Intricate interactions of magnesium and calcium are basic to all living cells and some are quite early on the evolutionary scale (92). For example, it was shown in the amoeba almost a century ago (93) that magnesium prevents calcium entry into the cell when calcium is present in excess. In addition, magnesium prevents calcium exit during calcium-deficient conditions and “in the presence of magnesium, less calcium is required for optimum movement” (93) in these one-celled animals. These basic cellular calcium-magnesium interactions are at work in human cells (94, 95), in which the imbalance of these 2 essential minerals can give rise to cellular phenotypes manifesting the physiologic symptoms of modern chronic diseases (96).

Change in calcium intake may affect magnesium balance and vice versa

Two comprehensive reviews of pre-1970 human studies on the impact of calcium intake on magnesium balance showed that with magnesium intakes <4 mg · kg⁻¹ · d⁻¹, there was magnesium loss regardless of calcium intake; however, when magnesium intakes were ≥5 mg · kg⁻¹ · d⁻¹, increases in calcium intake resulted in less magnesium retention (97, 98). Note that the current adult DRIs for magnesium are based on intakes of 4.3 mg · kg⁻¹ · d⁻¹ to maintain balance in healthy adults (60), and human studies found this factor to be 2.36 mg · kg⁻¹ · d⁻¹ (95% CI: 1.58, 3.38 mg · kg⁻¹ · d⁻¹) (99). Calcium intakes as high as 2–2.5 g/d caused lower magnesium absorption in 2 small, earlier studies (100, 101). In a study in teenaged girls, magnesium balance was negative with calcium intakes of 1800 mg/d; however, compared with positive magnesium balance results with 800 mg calcium/d, the differences in magnesium absorption, excretion, and balance were not significant in this small crossover trial (n = 5) (102). In a randomized clinical trial conducted in New Zealand menopausal women, researchers observed that the consumption of milk high in calcium or supplementation (1200 mg calcium) with or without magnesium significantly increased magnesium urinary excretion during the 8 h of consumption (103). Another trial in Thai menopausal women found that supplementation with 750 mg calcium for 3 mo led to a 15% increase in urinary excretion of magnesium, but the increase was not significant (104). A third trial conducted in women aged 24–34 y in The Netherlands found that 400 mg calcium in the form of salts or in cheese increased urinary excretions of magnesium (105). Although these findings are not entirely consistent and no dietary magnesium intakes were measured, these clinical trials indicate that high calcium supplementation may affect urinary magnesium excretion in women aged ≥24 y.

With regard to magnesium intakes affecting calcium balance, earlier studies showed that healthy adults with both low magnesium and low calcium intakes had a negative calcium balance, which was attenuated and reversed when magnesium intake improved (97, 98). More recently, a randomized trial of magnesium supplementation, conducted in Ireland, found that increasing magnesium intake from 11 mmol/d (264 mg/d) to ~22 mmol/d (528 mg/d) for 28 d did not increase urinary excretion of calcium among women aged 20–28 y (106). Another randomized trial conducted in women aged ~40 y in South Africa also found that magnesium supplementation at 250 mg/d (10.3 mmol/d) did not change urinary excretion of calcium, but it reduced fractional absorption of calcium by 23.5%, which was not caused by direct competition between the 2 minerals (107). However, a third trial conducted in men aged 21–42 y in Japan found that supplementation of 250 mg magnesium (as MgO) significantly elevated the urinary excretion of calcium (108). Note that the Japanese population has a low calcium to magnesium ratio (109).
**High calcium to magnesium ratios in the United States**

Over the past ≥30 y in the United States, both dietary calcium and magnesium intakes have increased. However, calcium intakes increased at a rate 2–2.5 times that of dietary magnesium intakes, giving rise to an increasing calcium to magnesium ratio in this population (Figure 2). This trend appears to have either reversed or leveled off during 2011–2012, but further surveys are needed to determine which trend, if either, is occurring. Compared with the increases in mean magnesium intakes in US adults (increases of 15.5% and 25% for men and women, respectively; see above) from 1977 to 2011–2012, mean calcium intakes from these same surveys (59, 63–70) showed increases of 37% in men (from 815 to 1117 mg calcium/d; r = 0.92, P = 0.0005) and 51% in women (from 570 to 862 mg calcium/d; r = 0.95, P = 0.0001). As a result, the mean calcium to magnesium ratio in US adults increased significantly between 1977 and 2012 (for men: r = 0.92, P = 0.0005; for women: r = 0.89, P = 0.001); in 2001, the mean calcium to magnesium ratio increased from <3.0 to >3.0 for both men and women (Figure 2). Increases in mean calcium and magnesium intakes were 3–6 and 1.5–3 times the increases in kilocalories, respectively (17% for women and 6% for men). This high calcium to magnesium ratio appears to be exacerbated by supplement usage, especially in women (110).

**Impact of calcium to magnesium ratios on disease outcomes**

Traditional advice is to maintain dietary calcium to magnesium ratios close to 2.0 for optimal health outcomes in humans (111) came from knowledgeable speculation that was not supported by any experimental evidence. In 2007, a colorectal neoplasia study by Dai et al. (71) provided evidence for an optimal dietary calcium to magnesium ratio (i.e., <2.8). In this case-control study (n = 2204), the risk of colorectal adenoma was reduced only in subjects with a calcium to magnesium ratio <2.8, although this risk decreased with increasing total magnesium intakes regardless of confounders. Among those with a calcium to magnesium ratio >2.8, total magnesium intake was not related to risk, although increasing total calcium intake showed a trend toward greater risk. Thus, total calcium intakes may be related to a reduced risk of colorectal adenoma only when calcium to magnesium ratios are <2.8. Dai et al. also found a nutrient-gene interaction [i.e., transient receptor potential melastatin 7 (TRPM7) with dietary Ca:Mg] in relation to the risk of both colorectal adenoma and hyperplastic polyps. TRPM7 is a newly identified gene that is essential to magnesium homeostasis, and the Thr14821le rs8042919 polymorphism in the TRPM7 gene is functional. Individuals with the 14821le allele and calcium to magnesium ratios >2.8 had a 60% greater risk of colorectal adenoma and an 85% increased risk of hyperplastic polyps than those without the 14821le allele in the TRPM7 gene (71).

A follow-up randomized clinical trial in 930 subjects (112) found that long-term calcium treatment (1200 mg/d over a 4-y period) significantly reduced colorectal adenoma recurrence risk but only when the baseline calcium to magnesium ratio was <2.6 (RR: 0.68; 95% CI: 0.52, 0.90). By contrast, calcium supplementation had no effect among subjects when the calcium to magnesium ratio was >2.6 (RR: 0.98; 95% CI: 0.75, 1.2). This effect modification by the calcium to magnesium ratio cannot solely be attributed to the baseline dietary intake of calcium or magnesium (112). These results show that the interpretation of studies measuring either calcium or magnesium intake alone is difficult, especially because food sources of calcium and magnesium are positively correlated (113).

**Opposite influence of low calcium to magnesium ratios on health outcomes**

Just as a calcium to magnesium ratio >2.6–2.8 can result in a detrimental effect, baseline calcium to magnesium ratios <2.0 may also have a detrimental effect. The Shanghai Women’s Health Study and the Shanghai Men’s Health Study are 2 population-based cohorts with >130,000 participants. These studies were conducted in a Chinese population in whom magnesium intakes are comparable to the US population; however, the median calcium to magnesium ratio (~1.7) is much lower than the calcium to magnesium ratio in the US population (≥3.0) (114). In this population with very low calcium to magnesium ratios, magnesium intakes at or above RDA levels were associated with an increased risk of total mortality in both women and men. This is in contrast with US studies undertaken with a high background calcium to magnesium ratio (≥3.0), which showed decreased mortality when magnesium intakes were increased by 200–375 mg/d (7, 13, 115, 116).

Furthermore, in the Chinese studies, among those with calcium to magnesium ratios >1.7, a magnesium intake ≥320 mg/d was significantly associated with reduced risks of total mortality and mortality due to ischemic heart disease (IHD) among men and mortality due to all cancers among women. By contrast, when calcium to magnesium ratios were ≤1.7, magnesium intake ≥320 mg/d was significantly related to increased risks of all-cause mortality and mortality due to CVD and colorectal cancer among women.

In addition, one study measuring both serum calcium and magnesium found that elevated serum magnesium was significantly associated with a lower risk of high-grade prostate cancer (OR: 0.26; 95% CI: 0.09, 0.85), whereas an elevated serum calcium to magnesium ratio was associated with an increased risk of high-grade prostate cancer (OR: 2.81; 95% CI: 1.24, 6.36) adjusted for serum calcium and magnesium (50). Another study with an examination of serum concentrations of calcium, magnesium, and phosphorus in a large population of whites and African Americans (27%) indicated that when serum magnesium is low and calcium and phosphorus are higher, this leads to a greater risk of heart failure (117). With the use of NHANES data, a recent study found that women who met the RDA for
both magnesium and calcium had the greatest reduced odds of MetS (OR: 0.59; 95% CI: 0.45, 0.76). In men, meeting the RDA showed no association with MetS, but those with intakes in the highest quartile for magnesium (≥386 mg/d) and calcium (≥1224 mg/d) had lower odds of MetS (OR: 0.74; 95% CI: 0.59, 0.93) (118).

In skeletal studies, magnesium depletion was associated with decreased osteoblastic and increased osteoclastic activity (40), lower bone mineral density (BMD) (32, 34, 36), and fragility. Most studies suggest that magnesium intake favorably alters BMD. In a study by Orchard et al. (33) that used data from the Women’s Health Initiative, a lower magnesium intake was associated with lower BMD of the hip and whole body, as expected; however, this did not translate into an increased risk of hip or total fractures. In the same study, excess magnesium appeared to be detrimental to bone and fracture risk of the forearm and wrist. The authors speculated that greater physical activity, made more likely by increased magnesium intakes, was responsible for this unexpected result. It would have been interesting to see whether calcium intakes and calcium to magnesium ratios might have further explained this detrimental outcome of higher magnesium intakes (33).

Together, these findings suggest that any magnesium or calcium effect is dependent on the intake amount of calcium or magnesium, respectively, and thus on the calcium to magnesium ratio. Furthermore, dietary intake studies of either magnesium or calcium alone may be unwittingly confounded by the unmeasured calcium or magnesium. These findings are relevant to the US population (and other populations experiencing an increased Ca:Mg) because the calcium to magnesium ranges that show these modifying effects (i.e., <1.7 in the Chinese study and >2.6–2.8 in the US studies) are well below the current mean calcium to magnesium ratio in US adults, which was 3.1–3.2 in 2007–2008 (119) and increased to 3.3–3.4 in 2009–2010 (Figure 2) from food intakes alone (i.e., not including supplements).

It appears that too much or too little of either calcium or magnesium might not be beneficial and there may be an optimal range of human calcium and magnesium intake. Studies in this area might expand our knowledge of when supplementation with magnesium or calcium is helpful or detrimental. Long-term exposure to a diet with a high calcium to magnesium ratio, which is common in the United States, may lead to public health concerns and requires further study.

**Vitamin D**

**Magnesium interactions with vitamin D**

There has been a recent surge of positive studies for several human health issues with vitamin D in the peer-reviewed literature, giving rise to medical prescriptions for and over-the-counter sales of high doses of vitamin D to increase serum vitamin D concentrations. With early studies showing an effect of magnesium on vitamin D status in patients with clinically diagnosed magnesium deficiency (23, 120–125), it is important to review the possible effects of both nutrients on one another in a general population with largely suboptimal magnesium intake (see above).

**Vitamin D Status**

Vitamin D deficiency causes rickets in children and osteomalacia in adults (126). Many epidemiologic studies suggest that low vitamin D status may also be associated with all-cause mortality (127–129) and with the risk of nonskeletal chronic diseases such as T2D (130–132), CVD (133, 134), and colorectal cancer (135–137). However, findings have not been entirely consistent (138–141). Large-scale clinical trials of vitamin D supplementation are ongoing (138, 139, 142). Despite food fortification and dietary supplementation, low vitamin D status (<20 μg/L or <50 nmol/L; Table 3) is still relatively common in the United States (143). In addition, there is large interindividual variation in serum 25-hydroxyvitamin D [25(OH)D] concentrations that is unexplained by dietary intake of vitamin D and sun exposure alone (144, 145).

**Magnesium is a cofactor in several steps of vitamin D biosynthesis and activation**

Magnesium, the second most abundant intracellular cation, plays a critical role in the synthesis and metabolism of parathyroid hormone (PTH) and vitamin D (123, 146, 147). Previous studies showed that the activities of 3 major enzymes that determine 25(OH)D concentrations, 25-hydroxylase, 1α-hydroxylase, and 24-hydroxylase (123, 147, 148), as well as vitamin D binding protein (VDBP) (123), are magnesium dependent. Magnesium deficiency leads to reduced 1,25-dihydroxyvitamin D [1,25(OH)₂D] and impaired PTH response (123) and has been implicated in magnesium-dependent, vitamin D–resistant rickets (146). In 2 case studies of vitamin D–resistant rickets, magnesium supplementation substantially reversed the resistance to vitamin D treatment (146), whereas intramuscular infusion of vitamin D as high as 600,000 IU alone did not lead to any improvement in biochemical features of advanced vitamin D deficiency (i.e., serum calcium, magnesium, phosphorus, and alkaline phosphatase; serum vitamin D was not measured) (146). On the other hand, 2 small clinical studies with no placebo arm conducted in magnesium-deficient patients (123, 149) found that magnesium infusion alone led to a nonsignificant increase in both 25(OH)D and 1,25(OH)₂D (123), whereas magnesium infusion plus oral vitamin D as 25(OH)D substantially increased both serum 25(OH)D and 1,25(OH)₂D (149). Thus, these findings showed no effect for a high dose of vitamin D alone or magnesium infusion alone; however, there was a substantial increase in serum 25(OH)D due to vitamin D supplementation with magnesium infusion. Taken together, these findings suggest that a possible interaction between magnesium and vitamin D influences vitamin D status (150), but these findings should be tested in a large clinical trial.
Effects of interaction between nutritional magnesium status and serum vitamin D on disease outcomes

On the basis of this biological plausibility, one recent NHANES study found that a high intake of total, dietary, or supplemental magnesium was independently and significantly associated with reduced risks of both vitamin D deficiency and insufficiency in the general population (150). In addition, an inverse association between total magnesium intake and vitamin D insufficiency primarily appeared among populations at high risk of vitamin D insufficiency, such as overweight/obese individuals and African Americans. Furthermore, this study also found inverse associations of serum 25(OH)D with mortality (particularly CVD and colorectal cancer) that were modified by high magnesium intake (i.e., the inverse associations were primarily present when the magnesium intake was above the median).

The critical role of magnesium in the synthesis of VDBP, PTH, 25(OH)D, and 1,25(OH)2D may partially explain why these inverse associations between serum 25(OH)D and the risk of all-cause mortality and mortality due to colorectal cancer and CVD primarily existed among those with magnesium intakes above the median. High magnesium intakes may increase the availability of 1,25(OH)2D by activating the synthesis of 25(OH)D and 1,25(OH)2D and increasing the transfer to target tissues by elevating VDBP. This explanation is supported by 2 case studies reported by Reddy and Sivakumar (146), in which magnesium supplementation substantially reversed the resistance to vitamin D treatment in magnesium-deficient patients.

A previous clinical study found that parenteral magnesium treatment without vitamin D replacement in 23 magnesium-deficient patients led to a normalizing of VDBP. The study also reported a 12% increase in serum 25(OH)D and a 30% increase in serum 1,25(OH)2D; however, neither of these changes was significant (123). In a subsequent study in 5 magnesium-deficient patients, intramuscular treatment with magnesium alone did not significantly increase serum 25(OH)D, but magnesium infusion together with a pharmacologic dose of 25(OH)D substantially increased both serum 25(OH)D and 1,25(OH)2D among patients with magnesium deficiency (149). One interpretation is that magnesium treatment does not affect 25(OH)D status (123, 149). However, it is also possible that several factors may have contributed to the nonsignificant increase in 25(OH)D status. First, the patients with magnesium deficiency who participated in these previous studies had low concentrations of 25(OH)D and 1,25(OH)2D as well as pre- vitamin D3 and vitamin D3 (cholecalciferol) as a result of limited sunlight exposure, underlying disease, and/or lack of oral supplementation. Therefore, concentrations of 25(OH)D and 1,25(OH)2D did not substantially increase during short-term magnesium repletion because pre- vitamin D3 was not available in sufficient amounts. Second, a modest increase in the conversion of 25(OH)D to 1,25(OH)2D resulted in a reduction in 25(OH)D concentrations (147). Finally, the sample size in these 2 studies may have been too small to show a significant moderate effect of magnesium treatment on vitamin D status.

Similar health effects of vitamin D and magnesium studies

Vitamin D and magnesium studies have shown similar associations in several aspects of human health (151) (Table 1). In these areas of human disease, vitamin D and magnesium may potentially confound each other or a possible interaction between the 2 may exist. However, almost all studies in these areas measured either vitamin D or magnesium status, not both. This may hamper interpretation of the results. For example, results of studies examining associations between magnesium intake and risk of stroke (6, 152) and IHD (116, 152) have been inconsistent. A meta-analyses of prospective studies found that magnesium intake was related to a significantly reduced risk of stroke; however, this inverse association was weak (an 8% reduction in risk per 100-mg magnesium/d increment) and only 1 of the 7 cohorts included in the meta-analysis found a significant inverse association (6). Likewise, a prospective cohort study showed that magnesium intake was nonsignificantly inversely associated with IHD, with a pooled RR of 0.86 (95% CI: 0.67, 1.10) for the highest quintile (mean magnesium intake: 433 mg/d) vs. the lowest quintile (mean magnesium intake: 255 mg/d) of intake category (152). However, it must be noted that 255 mg magnesium/d was found to be adequate for healthy human adults in a series of metabolic unit magnesium balance studies (99). Similar to these findings in studies on stroke and IHD, several studies evaluated the associations between magnesium intake and the risk of colorectal adenoma and cancer and the results were also not entirely consistent (48, 71, 153, 154). All of these studies examined associations of disease with magnesium intake only, without considering any interaction with vitamin D. The significant interactions between serum vitamin D and magnesium intakes in relation to mortality due to CVD and colorectal cancer might help to explain such inconsistencies.

Although findings on the potential interaction between vitamin D and magnesium have been promising, only one recent study, to our knowledge, examined the interaction between vitamin D and magnesium in the general population (150). Deng et al. (150) found that magnesium intake may contribute to vitamin D status and that associations between serum vitamin D and mortality risk may be modified by magnesium intake. Because there is currently only one available study, it is difficult to discern whether these 2 micronutrients act independently or synergistically. Future studies are warranted to replicate the findings of Deng et al. and to explore the biochemical basis and molecular mechanisms that would explain these findings.

Areas in need of study on the interaction between magnesium, calcium, and vitamin D

Normal vitamin D metabolism requires Mg2+ for its synthesis and metabolism of parathyroid hormone and vitamin D...
recommendation that the calcium to magnesium ratio should be lower than 2.8 to maintain health, supporting a long-held but non-evidence-based belief. Studies showed that a calcium to magnesium intake ratio <2.8 is critical for optimal health. A high calcium intake can exacerbate the onset of low magnesium status and vice versa. Studies have indicated that phosphorus nutrition affects populations with low magnesium intake and dietary calcium intake in US adults increased 2 times more than dietary magnesium intake between 1977 and 2010. Oral vitamin D has recently been recommended to support bone health, but data on possible interactions of these 2 micronutrients in human health and disease are very limited. Thus, additional studies are warranted. Increasing calcium to magnesium ratios coupled with oral calcium and vitamin D supplement recommendations in the face of suboptimal magnesium intakes may be affecting health via unstudied impacts of interactions between magnesium, calcium, and vitamin D.

Conclusions
The essential micronutrients magnesium, calcium, and vitamin D are each associated with chronic diseases of global concern, including CVD, T2D, MetS, and skeletal disorders. Dietary intakes of magnesium in the US population are low, and dietary calcium intakes in US adults increased 2–2.5 times more than dietary magnesium intakes between 1977 and 2010. Oral vitamin D has been recommended and is widely available. Despite these changes in intakes, research on the interactions between these 3 essential nutrients has been sparse.

Measuring magnesium status presents challenges, but magnesium intake is low in populations who consume a modern processed-food diet, including individuals in the United States. High calcium intakes can exacerbate the onset of low magnesium status and vice versa. Studies showed that a calcium to magnesium intake ratio <2.8 is critical for optimal health, supporting a long-held but non-evidence-based recommendation that the calcium to magnesium ratio should be close to 2. Increasing calcium intakes in the United States since 1977 have resulted in a calcium to magnesium ratio >3.0 since 2000, coinciding with increasing rates of T2D and colorectal cancer. US studies assessing oral magnesium therapy or dietary magnesium intakes showed beneficial effects of dietary magnesium in CVD, T2D, and cancers, although similar studies in populations with lower calcium to magnesium ratios (≥1.7) reported the opposite, showing the impact that background dietary calcium and/or magnesium can have on studies of either calcium or magnesium alone.

Low vitamin D status is associated with chronic diseases of global concern, as is low magnesium status. Magnesium is a cofactor for vitamin D biosynthesis, transport, and activation. Interactions between magnesium intake and serum vitamin D contributing to the risk of CVD and colorectal cancer were recently indicated. However, epidemiologic studies are warranted. Increasing calcium to magnesium ratios coupled with oral calcium and vitamin D supplement recommendations in the face of suboptimal magnesium intakes may be affecting health via unstudied impacts of interactions between magnesium, calcium, and vitamin D.

Acknowledgments
All authors read and approved the final manuscript.

References


